AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
AbCellera (Nasdaq: ABCL) said it will report top-line results from its Phase 2 trial of ABCL635 for moderate-to-severe vasomotor symptoms due to menopause before market open on Aug. 10, 2026, and hold a conference call at 4:30 a.m. PT. The randomized, double-blind, placebo-controlled study enrolled about 80 postmenopausal women.
How this was made
The 30-second read
Why it matters
The key new information is the exact timing of the top-line release and the conference call, enabling event-driven positioning ahead of efficacy and safety readouts.
Market read
This is a scheduled clinical catalyst with pre-market data release and a morning ET call, likely driving volatility and options activity into Aug 10.
What to watch
Traders may underweight that the article provides trial size (~80 women) and design but not endpoints or prior interim trends, increasing uncertainty into the release.
Background
AbCellera’s ABCL635 is a NK3R-targeting antibody drug in a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial for moderate-to-severe VMS due to menopause.
Ticker impact
AbCellera will release top-line Phase 2 results for ABCL635 before the open on Aug 10, 2026, with a live call at 7:30 a.m. ET.
Potentially high volatility around the Aug 10 pre-market release and the subsequent conference call, direction dependent on efficacy and safety signals.
The article discloses timing and trial design details but no efficacy/safety outcomes yet, so the immediate tradable variable is the upcoming data quality rather than a known result.
Market effects
Adds another data-point for non-hormonal menopause VMS antibody approaches and NK3R-targeting GPCR programs.
Limited, primarily US biotech event-driven flow into clinical-stage names.
Low, as the catalyst is company-specific and not a cross-market macro/regulatory event.
Counterpoint
If the Phase 2 readout is modest or safety signals emerge, the market may fade the catalyst quickly despite the strong event framing.
Key entities
- companyAbCellera
Clinical-stage biotech (Nasdaq: ABCL) running the Phase 2 trial for ABCL635.
- drug_programABCL635
Potential first-in-class antibody targeting NK3R for non-hormonal treatment of menopause-related VMS.
- clinical_trialPhase 2 trial (NCT07118891)
~80 postmenopausal women, randomized, double-blind, placebo-controlled; top-line results scheduled for Aug 10, 2026.
